ZIVO Bioscience (ZIVO) Competitors

ZIVO Bioscience (NASDAQ:ZIVO) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, profitability, risk, analyst recommendations, media sentiment, institutional ownership, community ranking, dividends and earnings.

Which has higher valuation and earnings, ZIVO or PLX?

Protalix BioTherapeutics has higher revenue and earnings than ZIVO Bioscience. ZIVO Bioscience is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ZIVO Bioscience	$30K	755.44	-$7.78M	-$3.80	-2.10
Protalix BioTherapeutics	$65.49M	1.31	$8.31M	$0.04	29.25

Is ZIVO or PLX more profitable?

Protalix BioTherapeutics has a net margin of 11.48% compared to ZIVO Bioscience's net margin of -11,068.75%. Protalix BioTherapeutics' return on equity of 19.48% beat ZIVO Bioscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ZIVO Bioscience	-11,068.75%	N/A	-677.15%
Protalix BioTherapeutics	11.48%	19.48%	7.82%

Do insiders and institutionals hold more shares of ZIVO or PLX?

12.8% of ZIVO Bioscience shares are owned by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are owned by institutional investors. 21.5% of ZIVO Bioscience shares are owned by insiders. Comparatively, 5.0% of Protalix BioTherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Do analysts rate ZIVO or PLX?

Protalix BioTherapeutics has a consensus target price of $10.00, suggesting a potential upside of 754.70%. Given Protalix BioTherapeutics' higher possible upside, analysts plainly believe Protalix BioTherapeutics is more favorable than ZIVO Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has more volatility & risk, ZIVO or PLX?

ZIVO Bioscience has a beta of 0.26, indicating that its share price is 74% less volatile than the S&P 500. Comparatively, Protalix BioTherapeutics has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500.

Does the MarketBeat Community prefer ZIVO or PLX?

ZIVO Bioscience received 94 more outperform votes than Protalix BioTherapeutics when rated by MarketBeat users. However, 62.50% of users gave Protalix BioTherapeutics an outperform vote while only 61.11% of users gave ZIVO Bioscience an outperform vote.

Company	Underperform	Outperform
ZIVO Bioscience	Outperform Votes 99 61.11%	Underperform Votes 63 38.89%
Protalix BioTherapeutics	Outperform Votes 5 62.50%	Underperform Votes 3 37.50%

Does the media refer more to ZIVO or PLX?

In the previous week, ZIVO Bioscience's average media sentiment score of 0.00 beat Protalix BioTherapeutics' score of -0.67 indicating that ZIVO Bioscience is being referred to more favorably in the media.

Company	Overall Sentiment
ZIVO Bioscience	Neutral
Protalix BioTherapeutics	Negative

Summary

Protalix BioTherapeutics beats ZIVO Bioscience on 12 of the 16 factors compared between the two stocks.